Researcher.Life Logo

Sarcoidosis Vasculitis and Diffuse Lung Diseases : Impact Factor & More

eISSN: 2532-179XpISSN: 1124-0490

Key Metrics

CiteScore
1.5
Impact Factor
< 5
SJR
Q4Internal Medicine
SNIP
0.54
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Sarcoidosis Vasculitis and Diffuse Lung Diseases

Sarcoidosis Vasculitis and Diffuse Lung Diseases Journal Specifications

Overview
Publisher MATTIOLI 1885
Language English
Frequency Quarterly
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year1996
Website URLVisit website
View less

Planning to publish in Sarcoidosis Vasculitis and Diffuse Lung Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Sarcoidosis Vasculitis and Diffuse Lung Diseases

Combined use of serum KL-6 and respiratory functional parameters for identifying fibrotic lung damage in SARS-CoV-2-induced interstitial pneumonia.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Combined impact of ROR2 and its ligands on the pathogenesis and prognosis of idiopathic pulmonary fibrosis.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Intrapulmonary unicentric Castleman's Disease: A clinical analysis of 8 patients.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Prognostic significance of incorporating SpO2 recovery time to the 6-minute walk test protocol and to a modified GAP index risk prediction model in patients with idiopathic pulmonary fibrosis.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Impact of pulmonary hypertension on mortality in progressive massive fibrosis.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Combined use of serum KL-6 and respiratory functional parameters for identifying fibrotic lung damage in SARS-CoV-2-induced interstitial pneumonia.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Combined impact of ROR2 and its ligands on the pathogenesis and prognosis of idiopathic pulmonary fibrosis.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Intrapulmonary unicentric Castleman's Disease: A clinical analysis of 8 patients.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Prognostic significance of incorporating SpO2 recovery time to the 6-minute walk test protocol and to a modified GAP index risk prediction model in patients with idiopathic pulmonary fibrosis.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Impact of pulmonary hypertension on mortality in progressive massive fibrosis.
  • 27 Mar 2026
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG

FAQs on Sarcoidosis Vasculitis and Diffuse Lung Diseases